文献速递疝与腹壁外科围术期管理与 ERAS

P4HB可吸收补片用于高并发症风险腹壁疝修补的60个月前瞻性多中心研究

Long-Term, Prospective, Multicenter Study of Poly-4-Hydroxybutyrate Mesh (Phasix Mesh) for Hernia Repair in Cohort at Risk for Complication: 60-Month Follow-Up.
PubMed 文献 · J Am Coll Surg · 2022-11-15

该前瞻性多中心研究评估聚-4-羟基丁酸酯(P4HB)补片在合并症患者CDC I类切口腹壁/切口疝修补中的长期结局,121例患者随访至60个月。Kaplan-Meier估计60个月疝复发率为22.0%,手术部位感染率为10.1%,再手术率14.9%,疼痛与生活质量较基线改善。

要点

  • 合并症患者使用P4HB补片行腹壁疝修补,60个月复发率22.0%,SSI率10.1%。
  • 再手术率14.9%,需干预的血清肿9例,疼痛与生活质量评分持续改善。
  • 该研究为P4HB补片长期结局提供预期框架,但随访完整率仅44.6%。

核心结论

  • 合并症患者使用P4HB补片行腹壁/切口疝修补,5年随访并发症不频繁且修补结局持久。

研究设计与样本

  • 前瞻性多中心研究,纳入121例合并症且CDC I类切口的腹壁/切口疝修补患者,平均年龄54.7±12.0岁,BMI 32.2±4.5 kg/m²。
  • 评估时间点为1、3、6、12、18、24、30、36和60个月,主要结局采用Kaplan-Meier时间-事件分析。

主要发现

  • 60个月Kaplan-Meier估计疝复发率为22.0±4.5%(95% CI 11.7%–29.4%),手术部位感染率为10.1±2.8%(95% CI 3.3%–14.0%)。
  • 需干预的血清肿9例,手术时间167.9±82.5分钟,住院时间5.3±5.3天,再手术18/121例(14.9%)。
  • 60个月时视觉模拟疼痛评分较基线变化-3.16±3.35 cm(n=52),Carolinas舒适总分较基线变化-24.3±21.4(n=52)。
  • 54例(44.6%)完成60个月随访。

临床怎么用

  • 对合并症且CDC I类切口的腹壁/切口疝患者,P4HB补片可作为可吸收补片修补的选项,需告知5年复发率约22%。
  • 术后应关注血清肿、手术部位感染及再手术风险,并长期随访疼痛与生活质量变化。

局限性

  • 60个月随访完整率仅44.6%,长期结局可能存在失访偏倚。
  • 单臂研究,无对照组,无法与合成永久补片或其他可吸收补片直接比较。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Long-term resorbable mesh represents a promising technology for ventral and incisional hernia repair (VIHR). This study evaluates poly-4-hydroxybutyrate mesh (P4HB; Phasix Mesh) among comorbid patients with CDC class I wounds. STUDY DESIGN: This prospective, multi-institutional study evaluated P4HB VIHR in comorbid patients with CDC class I wounds. Primary outcomes included hernia recurrence and surgical site infection. Secondary outcomes included pain, device-related adverse events, quality of life, reoperation, procedure time, and length of stay. Evaluations were scheduled at 1, 3, 6, 12, 18, 24, 30, 36, and 60 months. A time-to-event analysis (Kaplan-Meier) was performed for primary outcomes; secondary outcomes were reported as descriptive statistics. RESULTS: A total of 121 patients (46 male, 75 female) 54.7 ± 12.0 years old with a BMI of 32.2 ± 4.5 kg/m 2 underwent VIHR with P4HB Mesh (mean ± SD). Fifty-four patients (44.6%) completed the 60-month follow-up. Primary outcomes (Kaplan-Meier estimates at 60 months) included recurrence (22.0 ± 4.5%; 95% CI 11.7% to 29.4%) and surgical site infection (10.1 ± 2.8%; 95% CI 3.3 to 14.0). Secondary outcomes included seroma requiring intervention (n = 9), procedure time (167.9 ± 82.5 minutes), length of stay (5.3 ± 5.3 days), reoperation (18 of 121, 14.9%), visual analogue scale-pain (change from baseline -3.16 ± 3.35 cm at 60 months; n = 52), and Carolinas Comfort Total Score (change from baseline -24.3 ± 21.4 at 60 months; n = 52). CONCLUSIONS: Five-year outcomes after VIHR with P4HB mesh were associated with infrequent complications and durable hernia repair outcomes. This study provides a framework for anticipated long-term hernia repair outcomes when using P4HB mesh.

来源:J Am Coll Surg,查看原文。版权归原作者所有。

引用

  1. Roth JS, Anthone GJ, Selzer DJ, et al. Long-Term, Prospective, Multicenter Study of Poly-4-Hydroxybutyrate Mesh (Phasix Mesh) for Hernia Repair in Cohort at Risk for Complication: 60-Month Follow-Up. J Am Coll Surg. 2022. PMID: 36102523. doi:10.1097/XCS.0000000000000363

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。